This article was originally published in The Tan Sheet
Volume for Prilosec OTC (omeprazole magnesium) in the first quarter of 2006 more than doubled over the prior-year period, "driven largely by customer pre-buying ahead of the 10% price increase in mid-September and a base period suppressed by shipments allocation," the Cincinnati-based firm states during its first-quarter earnings call Nov. 1. The heartburn treatment continues to garner U.S. value share, which has grown by more than five points since 2005 to 36%, Treasurer John Goodwin stated. In oral care, Crest Pro-Health rinse has earned a 10% share of the mouthwash segment in the six months since its debut, Goodwin added. Overall, the healthcare business unit had "very strong top and bottom line results" during the quarter (ended Sept. 30), with sales increasing 13% to $2.1 bil. Net income grew 37% to $336 mil...
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.